NOT-DK-24-002: Notice of Change to Letter of Intent Due Date for RFA-DK-23-004: Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)

Notice of Change to Letter of Intent Due Date for RFA-DK-23-004: Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)

Notice Number:

NOT-DK-24-002

Key Dates

Release Date:

November 9, 2023

Related Announcements

October 11, 2023 - Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed). See NOFO RFA-DK-23-004.

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The purpose of this notice is to correct the reference to the Letter of Intent of RFA-DK-23-004. The Letter of Intent due date should be February 20, 2024. The NOFO has been updated as follows:
Currently Reads:
Key Dates
Posted Date October 11, 2023
Open Date (Earliest Submission Date) February 20, 2024
Letter of Intent Due Date(s) November 6, 2023

Modified to Read (in bold italics):
Key Dates
Posted Date October 11, 2023
Open Date (Earliest Submission Date) February 20, 2024
Letter of Intent Due Date(s) February 20, 2024

All other aspects of this NOFO remain the same.

Inquiries

Please direct all inquiries to:

Albert Hwa, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-1525
Email: [email protected]

Maggie Morris Fears, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-5444
Email: [email protected]